



SpectraCure presents the company and the progress on their current clinical trial

SpectraCure's CEO Masoud Khayyami will present the company and the progress on their current clinical trial today, November 13, 2017, at 14:00, at Sheraton Stockholm Hotel. The presentation will be sent live on the internet at www.aktiesparama.se/tv/live.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.